Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion on September 1, 2015. The Board of Directors of Samsung Pharmaceutical passed a resolution for the transaction on September 1, 2015. The transaction is expected to close on October 8, 2015.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5,190 KRW | -3.71% | +2.77% | +29.75% |
1st Jan change | Capi. | |
---|---|---|
+29.75% | 9.06M | |
-41.39% | 8.27B | |
+3.25% | 3.35B | |
-0.37% | 2.34B | |
-19.19% | 2.02B | |
-22.57% | 1.62B | |
+32.82% | 1.16B | |
-8.30% | 713M | |
+14.12% | 696M | |
-31.22% | 488M |
- Stock Market
- Equities
- A236340 Stock
- News MEDIZEN HUMANCARE Inc.
- Samsung Pharmaceutical Co., Ltd. agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion.